SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, CAR-T

June 04, 2021

Thoughts on Tmunity’s Decision to Drop TmPSMA-01: Will Companies Opt for More CAR-T Engineering or Better Drugs to Manage MAS?

Here is a brief preview of this blast: Tmunity recently disclosed that the FDA enforced the termination of their TmPSMA-01 (PSMA CAR-T) Ph1 trial in prostate cancer following the death of two patients (press release). Below, Celltelligence provides insights on how Tmunity’s PSMA CAR-T compares with key competitors Poseida (P-PSMA-101) and Autolus (AUTO7), while discussing how additional engineering or pharmacological intervention could be needed to improve CAR-T safety in solid tumors.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.